What You Should Know:
Yseop, a world-leading Generative AI company for life sciences, today announces the closing of a strategic investment round, with new investor Novartis (dRx Capital), joining existing investors Eli Lilly, NextStage AM and Wille Finance and celebrates its involvement in more than 150 clinical trials across the leading pharmaceutical companies in the world.Included in these clinical trials are many of the most notable advancements in new treatments, vaccines, and medicines
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Insights Management: A New Paradigm for Cancer Treatment
The cancer market for the pharma industry accounts for about a third of their product pipeline. With oncology drug sales set to top $390 billion by 2027, life science companies are aligning efforts to prioritize this critical market opportunity ahead of competitors.
The field of cancer presents unique challenges for the pharmaceutical industry, requiring innovative solutions to address high demand, intense competition, expensive research and development (R&D), complexities in drug
Read More
Cytovale Secures $84M for Transformative Sepsis Diagnostic Tool
What You Should Know:
Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced it has raised $84 million in Series C funding led by Norwest Venture Partners with participation by additional new investors Sands Capital and Global Health Investment Corporation (GHIC).The financing included participation from other new and existing investors, as well as the conversion of
Read More
Absci and AstraZeneca Sign $247M Partnership for AI-Powered Drug Discovery to Fight Cancer
What You Should Know:
- Absci Corporation (ABSI), a pioneer in using generative AI to discover antibodies, and AstraZeneca, a global biopharmaceutical leader, announced a collaboration today to develop an AI-designed antibody for cancer.
- This partnership combines Absci's cutting-edge Integrated Drug Creation™ platform with AstraZeneca's oncology expertise, aiming to accelerate the discovery of a potential new cancer treatment.
Absci's AI Engine Takes the Lead
Absci will leverage
Read More
PerkinElmer Acquires Covaris to Create Global Life-Sciences and Diagnostics Platform
What You Should Know:
- PerkinElmer, a leading global analytical services and solutions provider, announced its acquisition of Covaris, a developer of solutions for life science innovations.
- This strategic move will fuel Covaris' growth and expand PerkinElmer's life sciences portfolio into the high-growth diagnostics market. Notably, both companies share majority ownership under New Mountain Capital, making the integration potentially smoother. While financial details remain undisclosed,
Read More
QuantHealth Launches Katina: AI-Powered Platform for Clinical Trial Optimization
What You Should Know:
- QuantHealth, an AI-powered clinical trial design startup, today announced a major product upgrade to its platform with the launch of Katina, a new tool that utilizes AI to simulate clinical trials at scale, expedite, de-risk, and optimize drug development.
- The launch of Katina marks a new era in clinical trial optimization, powered by AI and massive real-world patient data. This innovative tool has the potential to revolutionize the way clinical trials are
Read More
Pepper Bio, the ’Google Maps for Drug Discovery’, Secures $6.5M to Streamline R&D
What You Should Know:
Pepper Bio, the “Google Maps for drug discovery,” today announced an oversubscribed $6.5 million seed round led by NFX with participation from Silverton Partners, Merck Digital Sciences Studio, Mana Ventures, Tensility Ventures, VSC Ventures, and more. Pepper Bio is the world’s first transomics company, which maps data across all the -omics layers and translates it into the fastest route for discovering new drugs, finding new uses for existing
Read More
Culmination Bio Raises $10M to Bring Longitudinal Health Data to Biopharma
What You Should Know:
Culmination Bio, a company building the largest disease-agnostic patient data intelligence platform, today announced a $10 million investment from Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures.As a spinoff from Intermountain Health, Culmination Bio maintains exclusive rights to a physical library and cloud-based data lake covering over 40 years of de-identified patient electronic health records and biospecimen data.
Data
Read More
Vivodyne Secures $38M for AI-Powered Drug Discovery Platform
What You Should Know:
- Vivodyne, a biotech company that accelerates drug discovery by testing therapies on lab-grown human organs raises $38M in total seed financing, led by Khosla Ventures, with participation from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures.
- The funding will support Vivodyne's development of a clinically predictive AI stack and discovery pipeline, which utilizes lab-grown human organ tissues to identify novel therapeutic targets and predict patient
Read More
IBM and Boehringer Ingelheim Partner on Generative AI for Transformative Antibody Therapeutics
What You Should Know:
- Boehringer Ingelheim and IBM announced a collaboration to leverage IBM's foundation model technologies for the discovery of novel candidate antibodies in drug development.
- The partnership will focus on utilizing IBM's pre-trained AI models to generate new human antibody sequences with desired properties, such as affinity, specificity, and developability. These models will be further fine-tuned on Boehringer Ingelheim's proprietary data to enhance their accuracy
Read More
